Abstract. The present study evaluated the association between programmed cell death ligand-1 (PD-L1) expression and long-term oncologic outcomes in colorectal cancer (CRC). PD-L1 expression was evaluated using immunohistochemistry in 175 patients who underwent surgical resection for CRC between September 1999 and August 2004. Patients were grouped according to PD-L1 expression, with 82 (46.9%) and 93 (53.1%) in the low and high PD-L1 expression groups, respectively. The overall survival (OS) and disease-free survival (DFS) rates were significantly better in the high expression group compared with in the low expression group (OS: 48.2 vs. 32.9%, P=0.047; DFS: 43.3 vs. 32.9%, P=0.021). According to the Tumor-Node-Metastasis stage subgroups, the OS rates in the low and high expression groups, respectively, were 66.7 and 60.0% in stage I (P=0.715), 51.8 and 46.7% in stage II (P=0.789), 19.6 and 51.1% in stage III (P=0.011) and 9.1 and 0% in stage IV (P=0.005). The DFS rates in the low and high expression groups, respectively, were 66.7 and 60.0% in stage I (P=0.715), 51.8 and 46.7% in stage II (P=0.857), 19.6 and 38.3% in stage III (P=0.006) and 9.1 and 0% in stage IV (P=0.700). The systemic recurrence rate was significantly higher in the low expression group compared with in the high expression group (42.7 vs. 12.9%, respectively, P=0.030). Low PD-L1 expression was significantly associated with tumor relapse and poor prognosis in stage III CRC.
Introduction
Colorectal cancer (CRC) is one of the most common types of cancer in Korea and other developed countries (1, 2) . The carcinogenesis of CRC is driven by genetic and epigenetic changes in tumor cells and is also influenced by tumor-host interactions (3) (4) (5) . Previous studies have reported the potential association of molecular markers such as BRAF, KRAS, and MMR with prognosis in patients with CRC (6, 7) . Identification of the predictors of poor prognosis and disease recurrence is important for the successful treatment of these patients and for the discovery of new therapeutic strategies.
Analysis of host immunity against human malignancy is increasingly important in cancer research and treatment (8, 9) . Immune checkpoints represent a major defense system of the tumor against antitumor immunity in the host and play an important role in suppressing the T-cell-mediated immune response in the tumor microenvironment (9, 10) . Programmed cell death ligand-1 (PD-L1) expression in tumor cells suppresses the cytotoxic activity of CD8-positive T-cells (11) (12) (13) . Up-regulation of PD-L1 has been reported in malignancies including lung cancer, esophageal cancer, renal cell carcinoma, ovarian cancer, CRC, and breast cancer and may play a central role in tumor-immune system interactions (14) (15) (16) (17) (18) (19) .
PD-L1 expression in tumor cells may be linked to a weakened host immune response, resulting in immune escape and an adverse prognosis in several malignancies (20) (21) (22) . However, the prognostic role of PD-L1 expression in CRC is less clear, with some studies reporting conflicting results as to whether PD-L1 expression indicates a better or worse prognosis. The prognostic evaluation in these studies has been limited because they included patients at various disease stages and different study populations (23) (24) (25) (26) (27) . The aim of this study was to evaluate the correlation between PD-L1 expression and long-term oncologic outcomes in CRC. Production of tissue microarray block. Formalin-fixed, paraffin-embedded tissue samples were produced for tissue microarray (TMA). Representative areas of each tumor were marked on each hematoxylin and eosin-stained slide and the corresponding area of the tissue blocks was sampled. The designated area of each donor block was collected using a tissue cylinder punch (3 mm diameter), and the samples were transferred to a recipient block.
Materials and methods

Patients
Immunohistochemistry. Sections (4 µm thickness) from the TMAs were cut in 10% formalin buffer, embedded in paraffin, mounted onto Superfrost Plus glass slides (VWR Scientific, West Chester, PA, USA), and incubated at 60˚C for 15 min. The slides were deparaffinized in xylene, rehydrated in graded alcohol solutions, and washed in tap water. Endogenous peroxidase activity was blocked by the addition of 3% H 2 O 2 . The slides were placed in a steam cooker filled with 10 mM sodium citrate buffer (pH 6.0) for antigen retrieval after treatment with a blocking agent (DAKO, Carpinteria, CA, USA) for 10 min to block nonspecific protein binding.
Immunohistochemistry for antigen (PD-L1) was performed using an autostainer (LV360-2D; LabVision Co., Fremont, CA, USA). Reagents and the secondary antibody from the commercial LP Kit (TL-125-HD, LabVision Co.) were used as provided by the manufacturer. The primary antibody was a rabbit polyclonal antibody against PD-L1 (1:400, Anti-PD-L1; AnaSpec, Fremont, CA, USA). Immunopositivity was evaluated by determining the proportions of positive cells (low, ≤50%; and high, >50%).
Evaluation parameters. The sixth edition of the American Joint Committee on Cancer (AJCC) classification system was used to determine the pathological tumor depth (pT), the number of metastasized lymph nodes (pN), and cancer stage. A postoperative clinical examination, measurement of serum carcinoembryonic antigen CEA levels, chest radiography every 3 months, and chest/abdominal computed tomography (CT) every 6 months were performed during each follow-up examination over a period of 3 years. After 3 years, the follow-up interval was changed to 6 months. Recurrence was defined as the presence of radiologically confirmed or histologically proven tumor and the location of recurrence was defined as the first site of recurrence after complete resection. Local recurrence was defined as any tumor recurrence in the surgical field; local recurrence with synchronous systemic recurrence was included systemic recurrence. The overall survival (OS) time was defined as the time from the date of surgery to the date of the latest follow-up visit or the date of death due to any cause, while the disease-free survival (DFS) time was defined as the time from surgery to any type of recurrence.
Statistical analyses. Data were expressed as medians with ranges. Differences in clinicopathological features between low and high-intensity PD-L1-positive CRCs were analyzed by Chi-square or Fisher's exact tests for categorical variables and Student's t-test for continuous variables. Survivals rate were determined using the Kaplan-Meier method and log-rank tests were used to compare survival rates among subgroups. Log-rank tests were also used for univariate analysis and independent prognostic factors were identified by multivariate analysis using the Cox proportional hazards model to calculate hazard ratios. All statistical tests were performed using IBM 
Results
Patient and tumor characteristics. PD-L1 expression was categorized as low in 82 (46.9%) patients and high in 93 (53.1%) patients ( Fig. 1) . The patient and tumor characteristics of the study cohort stratified by PD-L1 status are shown in Table I . The demographic characteristics were similar between the two cohorts for age, sex, preoperative carcinoembryonic antigen level, tumor stage, nodal stage, TNM stage, histology, lymphovascular invasion, and perinodal extension. There was a trend in tumors to be located in the right-sided colon, although without statistical significance, in the high PD-L1 expression group compared to the low PD-L1 expression group (22.6 vs. 12.2%, P=0.073).
Oncologic outcomes and recurrence pattern according to PD-L1 expression.
During the median follow-up period of 88 months (range 1-196 months), the total numbers of deaths (Table IV) .
Discussion
PD-L1 expression has been reported in tumor cells or tumor-infiltrating immune cells in several malignancies, including CRC, and may play a central role in immune-oncologic interactions (19, 28, 29) . The present study examined the effects of PD-L1 expression on long-term oncologic outcomes and recurrence patterns among patients with CRC. We found that PD-L1 expression was significantly associated with tumor recurrence and poor prognosis and was an independent prognostic factor for DFS, especially in stage III CRC. Moreover, the systemic recurrence rate was significantly The extraregional lymph node includes the para-aortic and lateral pelvic lymph node. higher and hepatic recurrence was more common in the low group than in the high expression group. Previous studies have reported conflicting results as to whether PD-L1 expression indicates a better or worse prognosis in CRC, possibly due to differences in study populations and designs (21, 23, 30) . In the present study, the prognostic impact of PD-L1 expression on long-term oncologic outcomes in CRC differed according to the TNM stage. In early stages, including stages I and II, there was no significant between-group difference; however, the long-term oncologic outcomes of patients with stage III disease was significantly better in the high PD-L1 expression group. In this context, our results underscore the specificities of tumor immune system interactions and microenvironments in CRC according to disease stage.
Our evaluation of the recurrence patterns according to the PD-L1 expression status revealed a significantly higher systemic recurrence rate in the low PD-L1 expression group than that in the high PD-L1 expression group. Moreover, low PD-L1 expression was significantly associated with hepatic recurrence. The high systemic recurrence rate and significant association with hepatic recurrence in the low PD-L1 expression group may be reflected in the poor prognosis.
CRC with MMR defects shows high microsatellite instability (MSI) and accounts for 12 to 15% of colorectal carcinomas. These tumors are infiltrated by higher numbers of lymphocytes and are characterized by a more favorable prognosis compared to those in MMR-proficient tumors. Some studies have reported different impacts of PD-L1 expression on survival according to microsatellite status. Dunne et al (26) demonstrated that PD-L1 expression was associated with a significantly worse recurrence-free survival in mismatch-repair-deficient tumors, whereas PD-L1 expression did not show a statistically significant association with recurrence-free survival in mismatch-repair-proficient tumors. In contrast, Droeser et al (23) reported that high PD-L1 expression in mismatch-repair-proficient CRC was associated with early tumor stage, absence of lymph node metastases, lower tumor grade, absence of vascular invasion, high numbers of tumor-infiltrating CD8+ T cells, and (26) used relapse follow-up data to find that patients with high PD-L1 expression had a significantly better outcome than that in patients with low expression in the untreated stage III population; however, the correlation between survival and high PD-L1 expression was lost in the stage III patients treated with adjuvant chemotherapy. They suggested that patients with high PD-L1 expression should not be administered 5-FU-based adjuvant chemotherapy following surgery. However, neither high nor low PD-L1 expression showed a statistically significant association with recurrence-free survival in our study, regardless of adjuvant chemotherapy (data not shown).
Our study has several limitations, including the small number of patients, its retrospective nature, and the lack of investigation of other immune-oncologic biomarkers such as MSI status, K-ras and BRAF mutations, and the expression of other immune checkpoints in tumor and immune cells. Further studies are needed to determine the possible association of MSI status with immune checkpoint molecules in tumor and immune cells in different stages or statuses.
Analysis of our long-term data indicates that love PD-L1 expression is significantly associated with tumor relapse and poor prognosis in CRC.
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